{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T17:05:33Z","timestamp":1794848733632,"version":"4.9.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010969","name":"Alzheimer Nederland","doi-asserted-by":"publisher","award":["WE.09-20921-04"],"award-info":[{"award-number":["WE.09-20921-04"]}],"id":[{"id":"10.13039\/501100010969","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We aimed to develop individualized predictions for risk of developing any-cause dementia and Alzheimer\u2019s disease (AD) dementia, in individuals with subjective cognitive decline (SCD) or mild cognitive impairment (MCI), using plasma phosphorylated-tau-181 (pTau181), phosphorylated-tau-217 (pTau217; in a subset), amyloid beta1-42\/1\u201340 (A\u03b242\/40), glial fibrillary acidic protein (GFAP) and\/or neurofilament light (NfL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      From the Amsterdam Dementia Cohort we included 314 individuals with SCD (age 61\u2009\u00b1\u20099\u00a0years,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009184 (59%) male, MMSE 29\u2009\u00b1\u20091) and 253 individuals with MCI (age 65\u2009\u00b1\u20097\u00a0years,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009165 (65%) male, MMSE 27\u2009\u00b1\u20092), who had annual follow-up (median duration 2.4\u00a0years). Cox proportional hazards regression models were used to calculate probabilities for progression to dementia and were externally validated in MEMENTO and AIBL cohorts.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During follow-up 20 SCD and 99 MCI patients developed dementia. For MCI patients who progressed to any form of dementia, plasma GFAP contributed on top of age, sex, and MMSE score in the parsimonious individualized prognostic model (C-index\u2009=\u20090.69 [95%CI\u2009=\u20090.63; 0.76]). With AD-dementia as the outcome, GFAP and pTau181 were selected in the parsimonious model on top of the demographic variables (C-index\u2009=\u20090.71 [95%CI\u2009=\u20090.65; 0.76]). In the subset of 197 MCI individuals with pTau217 measurements, pTau217 was selected in the parsimonious model on top of the demographic variables (C-index\u2009=\u20090.75 [95%CI\u2009=\u20090.69; 0.79]). External validation demonstrated that the models are robust in a memory clinic setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our prediction models have utility for clinical practice to calculate progression probabilities for development of dementia in individual patients living with MCI over a 1-, 3- and 5-year time period.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-025-01925-1","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T10:45:45Z","timestamp":1764758745000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Individualized prediction of clinical progression to dementia using plasma biomarkers in non-demented elderly"],"prefix":"10.1186","volume":"18","author":[{"given":"Madison I. J.","family":"Honey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid S.","family":"van Maurik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argonde C.","family":"van Harten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Gouda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mardou","family":"van Leeuwenstijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arenda","family":"Mank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin","family":"Trieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Bouteloup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve","family":"Ch\u00eane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Pellegrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Dufouil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Doecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin L.","family":"Masters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolande","family":"Pijnenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiesje M.","family":"van der Flier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte E.","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge M. W.","family":"Verberk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"issue":"3","key":"1925_CR1","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/joim.12190","volume":"275","author":"RC Petersen","year":"2014","unstructured":"Petersen RC, Caracciolo B, Brayne C, Gauthier S, Jelic V, Fratiglioni L. Mild cognitive impairment: a concept in evolution. J Intern Med. 2014;275(3):214\u201328.","journal-title":"J Intern Med"},{"issue":"10043","key":"1925_CR2","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","volume":"388","author":"P Scheltens","year":"2016","unstructured":"Scheltens P, Blennow K, Breteler MMB, de Strooper B, Frisoni GB, Salloway S, et al. Alzheimer\u2019s disease. Lancet. 2016;388(10043):505\u201317.","journal-title":"Lancet"},{"key":"1925_CR3","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.dadm.2019.04.011","volume":"11","author":"IS van Maurik","year":"2019","unstructured":"van Maurik IS, van der Kall LM, de Wilde A, Bouwman FH, Scheltens P, van Berckel BNM, et al. Added value of amyloid PET in individualized risk predictions for MCI patients. Alzheimers Dement (Amst). 2019;11:529\u201337.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"11","key":"1925_CR4","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/S1474-4422(19)30283-2","volume":"18","author":"IS van Maurik","year":"2019","unstructured":"van Maurik IS, Vos SJ, Bos I, Bouwman FH, Teunissen CE, Scheltens P, et al. Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. Lancet Neurol. 2019;18(11):1034\u201344.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1925_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-019-0487-y","volume":"11","author":"IS van Maurik","year":"2019","unstructured":"van Maurik IS, Slot RER, Verfaillie SCJ, Zwan MD, Bouwman FH, Prins ND, et al. Personalized risk for clinical progression in cognitively normal subjects-the ABIDE project. Alzheimers Res Ther. 2019;11(1):33.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1925_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227282","volume":"15","author":"LNC Visser","year":"2020","unstructured":"Visser LNC, van Maurik IS, Bouwman FH, Staekenborg S, Vreeswijk R, Hempenius L, et al. Clinicians\u2019 communication with patients receiving a MCI diagnosis: the ABIDE project. PLoS One. 2020;15(1):e0227282.","journal-title":"PLoS One"},{"issue":"1","key":"1925_CR7","volume":"14","author":"EH Thijssen","year":"2022","unstructured":"Thijssen EH, Verberk IMW, Kindermans J, Abramian A, Vanbrabant J, Ball AJ, et al. Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia. Alzheimer\u2019s & Dementia: Diagnosis, Assessment & Disease Monitoring. 2022;14(1):e12285.","journal-title":"Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring"},{"issue":"1","key":"1925_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-89004-x","volume":"11","author":"EH Thijssen","year":"2021","unstructured":"Thijssen EH, Verberk IMW, Vanbrabant J, Koelewijn A, Heijst H, Scheltens P, et al. Highly specific and ultrasensitive plasma test detects Abeta(1\u201342) and Abeta(1\u201340) in Alzheimer\u2019s disease. Sci Rep. 2021;11(1):9736.","journal-title":"Sci Rep"},{"issue":"8","key":"1925_CR9","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr.","year":"2024","unstructured":"Jack CR Jr., Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association workgroup. Alzheimers Dement. 2024;20(8):5143\u201369.","journal-title":"Alzheimers Dement"},{"issue":"7","key":"1925_CR10","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41582-024-00977-5","volume":"20","author":"SE Schindler","year":"2024","unstructured":"Schindler SE, Galasko D, Pereira AC, Rabinovici GD, Salloway S, Su\u00e1rez-Calvet M, et al. <article-title update=\"added\">Acceptable performance of blood biomarker tests of amyloid pathology \u2014 recommendations from the Global CEO Initiative on Alzheimer\u2019s Disease. Nat Rev Neurol. 2024;20(7):426\u201339.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"1925_CR11","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","volume":"21","author":"CE Teunissen","year":"2022","unstructured":"Teunissen CE, Verberk IMW, Thijssen EH, Vermunt L, Hansson O, Zetterberg H, et al. Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation. Lancet Neurol. 2022;21(1):66\u201377.","journal-title":"Lancet Neurol"},{"issue":"2","key":"1925_CR12","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1016\/S2666-7568(20)30061-1","volume":"2","author":"IMW Verberk","year":"2021","unstructured":"Verberk IMW, Laarhuis MB, van den Bosch KA, Ebenau JL, van Leeuwenstijn M, Prins ND, et al. Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. Lancet Healthy Longev. 2021;2(2):e87\u201395.","journal-title":"Lancet Healthy Longev"},{"issue":"5","key":"1925_CR13","doi-asserted-by":"publisher","first-page":"e473","DOI":"10.1212\/WNL.0000000000201479","volume":"100","author":"V Planche","year":"2023","unstructured":"Planche V, Bouteloup V, Pellegrin I, Mangin JF, Dubois B, Ousset PJ, et al. Validity and performance of blood biomarkers for Alzheimer disease to predict dementia risk in a large clinic-based cohort. Neurology. 2023;100(5):e473\u201384.","journal-title":"Neurology"},{"key":"1925_CR14","doi-asserted-by":"publisher","first-page":"695696","DOI":"10.3389\/fneur.2021.695696","volume":"12","author":"YL Wang","year":"2021","unstructured":"Wang YL, Chen J, Du ZL, Weng H, Zhang Y, Li R, et al. Plasma p-tau181 level predicts neurodegeneration and progression to Alzheimer\u2019s dementia: a longitudinal study. Front Neurol. 2021;12:695696.","journal-title":"Front Neurol"},{"issue":"1","key":"1925_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00804-9","volume":"13","author":"C Cicognola","year":"2021","unstructured":"Cicognola C, Janelidze S, Hertze J, Zetterberg H, Blennow K, Mattsson-Carlgren N, et al. Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. Alzheimers Res Ther. 2021;13(1):68.","journal-title":"Alzheimers Res Ther"},{"key":"1925_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12614","author":"H Stocker","year":"2022","unstructured":"Stocker H, Beyer L, Perna L, Rujescu D, Holleczek B, Beyreuther K, et al. Association of plasma biomarkers, p-tau181, glial fibrillary acidic protein, and neurofilament light, with intermediate and long-term clinical Alzheimer\u2019s disease risk: results from a prospective cohort followed over 17 years. Alzheimers Dement. 2022. https:\/\/doi.org\/10.1002\/alz.12614.","journal-title":"Alzheimers Dement"},{"key":"1925_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12745","author":"L Beyer","year":"2022","unstructured":"Beyer L, Stocker H, Rujescu D, Holleczek B, Stockmann J, Nabers A, et al. Amyloid-beta misfolding and GFAP predict risk of clinical Alzheimer\u2019s disease diagnosis within 17 years. Alzheimers Dement. 2022. https:\/\/doi.org\/10.1002\/alz.12745.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"1925_CR18","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s41591-021-01348-z","volume":"27","author":"S Palmqvist","year":"2021","unstructured":"Palmqvist S, Tideman P, Cullen N, Zetterberg H, Blennow K, Dage JL, et al. Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures. Nat Med. 2021;27(6):1034\u201342.","journal-title":"Nat Med"},{"issue":"1","key":"1925_CR19","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13195-022-00990-0","volume":"14","author":"A Pichet Binette","year":"2022","unstructured":"Pichet Binette A, Palmqvist S, Bali D, Farrar G, Buckley CJ, Wolk DA, et al. Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer\u2019s dementia in mild cognitive impairment patients. Alzheimers Res Ther. 2022;14(1):46.","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"1925_CR20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/00002093-200210000-00001","volume":"16","author":"WW Barker","year":"2002","unstructured":"Barker WW, Luis CA, Kashuba A, Luis M, Harwood DG, Loewenstein D, et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the state of Florida Brain Bank. Alzheimer Dis Assoc Disord. 2002;16(4):203\u201312.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"1","key":"1925_CR21","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jalz.2016.04.002","volume":"13","author":"RA Goodman","year":"2017","unstructured":"Goodman RA, Lochner KA, Thambisetty M, Wingo TS, Posner SF, Ling SM. Prevalence of dementia subtypes in United States Medicare fee-for-service beneficiaries, 2011\u20132013. Alzheimers Dement. 2017;13(1):28\u201337.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1925_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-019-0531-y","volume":"11","author":"AD Fruijtier","year":"2019","unstructured":"Fruijtier AD, Visser LNC, van Maurik IS, Zwan MD, Bouwman FH, van der Flier WM, et al. ABIDE delphi study: topics to discuss in diagnostic consultations in memory clinics. Alzheimers Res Ther. 2019;11(1):77.","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"1925_CR23","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.trci.2017.03.009","volume":"3","author":"M Kunneman","year":"2017","unstructured":"Kunneman M, Smets EMA, Bouwman FH, Schoonenboom NSM, Zwan MD, Pel-Littel R, et al. Clinicians\u2019 views on conversations and shared decision making in diagnostic testing for Alzheimer\u2019s disease: the ABIDE project. Alzheimer\u2019s & Dementia: Translational Research & Clinical Interventions. 2017;3(3):305\u201313.","journal-title":"Alzheimer's & Dementia: Translational Research & Clinical Interventions"},{"issue":"1","key":"1925_CR24","doi-asserted-by":"publisher","first-page":"e12189","DOI":"10.1002\/trc2.12189","volume":"7","author":"A Mank","year":"2021","unstructured":"Mank A, van Maurik IS, Bakker ED, van de Glind EMM, J\u00f6nsson L, Kramberger MG, et al. Identifying relevant outcomes in the progression of Alzheimer\u2019s disease; what do patients and care partners want to know about prognosis? Alzheimer\u2019s & Dementia: Translational Research & Clinical Interventions. 2021;7(1):e12189.","journal-title":"Alzheimer's & Dementia: Translational Research & Clinical Interventions"},{"issue":"2","key":"1925_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12401","volume":"9","author":"MAE Dreves","year":"2023","unstructured":"Dreves MAE, van Harten AC, Visser LNC, Rhodius-Meester H, K\u00f6hler S, Kooistra M, et al. Rationale and design of the ABOARD project (a personalized medicine approach for Alzheimer\u2019s disease). Alzheimer\u2019s & Dementia: Translational Research & Clinical Interventions. 2023;9(2):e12401.","journal-title":"Alzheimer's & Dementia: Translational Research & Clinical Interventions"},{"issue":"5","key":"1925_CR26","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/s43587-023-00404-2","volume":"3","author":"WM van der Flier","year":"2023","unstructured":"van der Flier WM, de Vugt ME, Smets EMA, Blom M, Teunissen CE. Towards a future where Alzheimer\u2019s disease pathology is stopped before the onset of dementia. Nat Aging. 2023;3(5):494\u2013505.","journal-title":"Nat Aging"},{"issue":"6","key":"1925_CR27","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/nrneurol.2010.54","volume":"6","author":"BC Stephan","year":"2010","unstructured":"Stephan BC, Kurth T, Matthews FE, Brayne C, Dufouil C. Dementia risk prediction in the population: are screening models accurate? Nat Rev Neurol. 2010;6(6):318\u201326.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"1925_CR28","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3233\/JAD-132306","volume":"41","author":"WM van der Flier","year":"2014","unstructured":"van der Flier WM, Pijnenburg YA, Prins N, Lemstra AW, Bouwman FH, Teunissen CE, et al. Optimizing patient care and research: the Amsterdam Dementia Cohort. J Alzheimers Dis. 2014;41(1):313\u201327.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"1925_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-018-0390-y","volume":"10","author":"RER Slot","year":"2018","unstructured":"Slot RER, Verfaillie SCJ, Overbeek JM, Timmers T, Wesselman LMP, Teunissen CE, et al. Subjective cognitive impairment cohort (SCIENCe): study design and first results. Alzheimers Res Ther. 2018;10(1):76.","journal-title":"Alzheimers Res Ther"},{"key":"1925_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14088","author":"IMW Verberk","year":"2024","unstructured":"Verberk IMW, Jutte J, Kingma MY, Vigneswaran S, Gouda M, van Engelen MP, et al. Development of thresholds and a visualization tool for use of a blood test in routine clinical dementia practice. Alzheimers Dement. 2024. https:\/\/doi.org\/10.1002\/alz.14088.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"1925_CR31","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr., Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):263\u20139.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"1925_CR32","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/WAD.0000000000000034","volume":"28","author":"P Sachdev","year":"2014","unstructured":"Sachdev P, Kalaria R, O\u2019Brien J, Skoog I, Alladi S, Black SE, et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord. 2014;28(3):206\u201318.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"1","key":"1925_CR33","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium. Neurology. 2017;89(1):88\u2013100.","journal-title":"Neurology"},{"issue":"Pt 9","key":"1925_CR34","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/brain\/awr179","volume":"134","author":"K Rascovsky","year":"2011","unstructured":"Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456\u201377.","journal-title":"Brain"},{"issue":"6","key":"1925_CR35","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU H\u00f6glinger","year":"2017","unstructured":"H\u00f6glinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32(6):853\u201364.","journal-title":"Mov Disord"},{"issue":"1","key":"1925_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-017-0288-0","volume":"9","author":"C Dufouil","year":"2017","unstructured":"Dufouil C, Dubois B, Vellas B, Pasquier F, Blanc F, Hugon J, et al. Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort. Alzheimers Res Ther. 2017;9(1):67.","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"1925_CR37","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1365-2796.2004.01380.x","volume":"256","author":"B Winblad","year":"2004","unstructured":"Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, et al. Mild cognitive impairment\u2013beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004;256(3):240\u20136.","journal-title":"J Intern Med"},{"issue":"1","key":"1925_CR38","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3233\/ADR-210005","volume":"5","author":"C Fowler","year":"2021","unstructured":"Fowler C, Rainey-Smith SR, Bird S, Bomke J, Bourgeat P, Brown BM, et al. Fifteen years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) study: progress and observations from 2,359 older adults spanning the spectrum from cognitive normality to Alzheimer\u2019s disease. J Alzheimers Dis Rep. 2021;5(1):443\u201368.","journal-title":"J Alzheimers Dis Rep"},{"issue":"1","key":"1925_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-022-01011-w","volume":"14","author":"PR Kac","year":"2022","unstructured":"Kac PR, Gonzalez-Ortiz F, Simr\u00e9n J, Dewit N, Vanmechelen E, Zetterberg H, et al. Diagnostic value of serum versus plasma phospho-tau for Alzheimer\u2019s disease. Alzheimers Res Ther. 2022;14(1):65.","journal-title":"Alzheimers Res Ther"},{"key":"1925_CR40","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-2288-13-33","volume":"13","author":"P Royston","year":"2013","unstructured":"Royston P, Altman DG. External validation of a Cox prognostic model: principles and methods. BMC Med Res Methodol. 2013;13:33.","journal-title":"BMC Med Res Methodol"},{"key":"1925_CR41","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-0-387-77244-8_3","volume-title":"Clinical prediction models: a practical approach to development, validation, and updating","author":"EW Steyerberg","year":"2009","unstructured":"Steyerberg EW. Study design for prediction models. In: Clinical prediction models: a practical approach to development, validation, and updating. New York, NY: Springer, New York; 2009. p. 33\u201352."},{"issue":"4","key":"1925_CR42","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jpsychires.2008.04.014","volume":"43","author":"AJ Mitchell","year":"2009","unstructured":"Mitchell AJ. A meta-analysis of the accuracy of the mini-mental state examination in the detection of dementia and mild cognitive impairment. J Psychiatr Res. 2009;43(4):411\u201331.","journal-title":"J Psychiatr Res"},{"issue":"6","key":"1925_CR43","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512\u201327.","journal-title":"JAMA"},{"issue":"12","key":"1925_CR44","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1001\/jamaneurol.2017.2712","volume":"74","author":"IS van Maurik","year":"2017","unstructured":"van Maurik IS, Zwan MD, Tijms BM, Bouwman FH, Teunissen CE, Scheltens P, et al. Interpreting biomarker results in individual patients with mild cognitive impairment in the Alzheimer\u2019s biomarkers in daily practice (ABIDE) project. JAMA Neurol. 2017;74(12):1481\u201391.","journal-title":"JAMA Neurol"},{"issue":"1","key":"1925_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00900-w","volume":"13","author":"S Grueso","year":"2021","unstructured":"Grueso S, Viejo-Sobera R. Machine learning methods for predicting progression from mild cognitive impairment to Alzheimer\u2019s disease dementia: a systematic review. Alzheimers Res Ther. 2021;13(1):162.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1925_CR46","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s43587-020-00003-5","volume":"1","author":"NC Cullen","year":"2021","unstructured":"Cullen NC, Leuzy A, Palmqvist S, Janelidze S, Stomrud E, Pesini P, et al. Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. Nature Aging. 2021;1(1):114\u201323.","journal-title":"Nature Aging"},{"issue":"1","key":"1925_CR47","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13195-020-00682-7","volume":"12","author":"IMW Verberk","year":"2020","unstructured":"Verberk IMW, Thijssen E, Koelewijn J, Mauroo K, Vanbrabant J, de Wilde A, et al. Combination of plasma amyloid beta((1\u201342\/1-40)) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. Alzheimers Res Ther. 2020;12(1):118.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1925_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-022-01005-8","volume":"14","author":"C Groot","year":"2022","unstructured":"Groot C, Cicognola C, Bali D, Triana-Baltzer G, Dage JL, Pontecorvo MJ, et al. Diagnostic and prognostic performance to detect Alzheimer\u2019s disease and clinical progression of a novel assay for plasma p-tau217. Alzheimers Res Ther. 2022;14(1):67.","journal-title":"Alzheimers Res Ther"},{"key":"1925_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101030","volume":"45","author":"PV Martino-Adami","year":"2024","unstructured":"Martino-Adami PV, Chatterjee M, Kleineidam L, Weyerer S, Bickel H, Wiese B, et al. Prognostic value of Alzheimer\u2019s disease plasma biomarkers in the oldest-old: a prospective primary care-based study. The Lancet Regional Health. 2024;45:101030.","journal-title":"The Lancet Regional Health"},{"issue":"6","key":"1925_CR50","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114022","volume":"13","author":"N Mattsson-Carlgren","year":"2021","unstructured":"Mattsson-Carlgren N, Janelidze S, Bateman RJ, Smith R, Stomrud E, Serrano GE, et al. Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO Mol Med. 2021;13(6):e14022.","journal-title":"EMBO Mol Med"},{"key":"1925_CR51","doi-asserted-by":"publisher","first-page":"1389595","DOI":"10.3389\/fnagi.2024.1389595","volume":"16","author":"CH Hsieh","year":"2024","unstructured":"Hsieh CH, Ko CA, Liang CS, Yeh PK, Tsai CK, Tsai CL, et al. Longitudinal assessment of plasma biomarkers for early detection of cognitive changes in subjective cognitive decline. Front Aging Neurosci. 2024;16:1389595.","journal-title":"Front Aging Neurosci"},{"issue":"11","key":"1925_CR52","doi-asserted-by":"publisher","first-page":"8216","DOI":"10.1002\/alz.14184","volume":"20","author":"MM Mielke","year":"2024","unstructured":"Mielke MM, Anderson M, Ashford JW, Jeromin A, Lin PJ, Rosen A, et al. <article-title update=\"added\">Recommendations for clinical implementation of blood\u2010based biomarkers for Alzheimer\u2019s disease. Alzheimers Dement. 2024;20(11):8216\u201324.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"1925_CR53","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/acps.12336","volume":"130","author":"AJ Mitchell","year":"2014","unstructured":"Mitchell AJ, Beaumont H, Ferguson D, Yadegarfar M, Stubbs B. Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: meta-analysis. Acta Psychiatr Scand. 2014;130(6):439\u201351.","journal-title":"Acta Psychiatr Scand"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01925-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-025-01925-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01925-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T14:03:35Z","timestamp":1767794615000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-025-01925-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1925"],"URL":"https:\/\/doi.org\/10.1186\/s13195-025-01925-1","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"15 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All human subjects provided informed consent to utilise their medical data and biospecimens for research. The study was approved by the Institutional Ethical Review Board of the Amsterdam University Medical Centers and performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study was executed under the umbrella of the Dutch ABOARD project (http:\/\/www.aboard-project.nl). Research of the Neurochemistry Lab and Alzheimer Center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting Steun Alzheimercentrum Amsterdam. The chair of Wiesje van der Flier is supported by the Pasman stichting. MH, CET and WF are recipients of ABOARD, which is a public\u2013private partnership receiving funding from ZonMW (#73305095007) and Health\u2009~\u2009Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). More than 30 partners participate in ABOARD (www.aboard-project.nl), one of which is the Dutch Brain Foundation (Hersenstichting). The SCIENCe project receives funding from stichting Dioraphte. AH`s research is funded by Alzheimer Nederland, ZonMW and the Alzheimer Drug Discovery Foundation. She served as a consultant for Lilly and is an advisory board member for the brain research center. IM\u2019s research is funded by ZonMW and STI-MAG. IM received a consultancy fee (paid to the university) from Roche. IV\u2019s research is funded by Health\u2009~\u2009Holland and Amsterdam UMC. She serves as a consultant for Neurogen Biomarking (paid directly to the institution). Research of CET is supported by the European Commission (Marie Curie International Training Network, grant agreement No 860197 (MIRIADE) and TAME, Innovative Medicines Initiatives 3TR (Horizon 2020, grant no 831434) EPND (IMI 2 Joint Undertaking (JU), grant No. 101034344) and JPND (bPRIDE, CCAD), European Partnership on Metrology, co-financed from the European Union\u2019s Horizon Europe Research and Innovation Programme and by the Participating States ((22HLT07 NEuroBioStand), CANTATE project funded by the Alzheimer Drug Discovery Foundation, Alzheimer Association, Michael J Fox Foundation, Health Holland, the Dutch Research Council (ZonMW), Alzheimer Drug Discovery Foundation, The Selfridges Group Foundation, Alzheimer Netherlands. CET is recipient of ABOARD, which is a public\u2013private partnership receiving funding from ZonMW (#73305095007) and Health\u2009~\u2009Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). CET is recipient of TAP-dementia, a ZonMw funded project (#10510032120003) in the context of the Dutch National Dementia Strategy. CET has research contracts with Acumen, ADx Neurosciences, AC-Immune, Alamar, Aribio, Axon Neurosciences, Beckman-Coulter, BioConnect, Bioorchestra, Brainstorm Therapeutics, Celgene, Cognition Therapeutics, EIP Pharma, Eisai, Eli Lilly, Fujirebio, Instant Nano Biosensors, Novo Nordisk, Olink, PeopleBio, Quanterix, Roche, Toyama, Vivoryon. She is editor in chief of Alzheimer Research and Therapy, and serves on editorial boards of Molecular Neurodegeneration, Neurology: Neuroimmunology & Neuroinflammation, Medidact Neurologie\/Springer, and serves on committee to define guidelines for Cognitive disturbances, and one for acute Neurology in the Netherlands. She had consultancy\/speaker contracts for Aribio, Biogen, Beckman-Coulter, Cognition Therapeutics, Eli Lilly, Merck, Novo Nordisk, Olink, Roche and Veravas. All other authors have nothing to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}